Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Fresno, California and other locations
Dates
study started
study ends around
Principal Investigator
by Haifaa Abdulhaq, MD

Description

Summary

This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and venetoclax together may work better in treating follicular lymphoma compared to each drug alone.

Official Title

A Phase II Trial of the Combination of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

Details

Keywords

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Lymphoma, Follicular Lymphoma, Venetoclax, Obinutuzumab, Ibrutinib

Eligibility

Locations

  • UCSF (UCSF) Fresno accepting new patients
    Fresno California 93701 United States
  • University of California Davis Comprehensive Cancer Center accepting new patients
    Sacramento California 95817 United States
  • University of California, Los Angeles not yet accepting patients
    Los Angeles California 90095 United States
  • University of California, San Diego accepting new patients
    San Diego California 92037 United States

Lead Scientist at UCSF

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Joseph Tuscano
ID
NCT04450173
Phase
Phase 2 Lymphoma Research Study
Study Type
Interventional
Participants
Expecting 40 study participants
Last Updated